Search results for "ADENOCARCINOMA"

showing 10 items of 589 documents

Chemotherapy of metastatic colon cancer in France: A population-based study

2021

International audience; Aims: to describe, using data from a cancer registry in a well-defined French population, the therapeutic strategies and survival of patients with metastatic colon cancer (mCC).Methods: all patients with synchronous mCC diagnosed within the 2005-2014 period recorded in the digestive cancers registry of Burgundy were included.Results: 1286 mCC patients were included (57% male), of which 34.5% did not receive any antitumor treatment. Both, advanced age (≥75 years) and the Charlson comorbidity score ≥2 were significantly associated with the absence of antitumor treatment. Among the patients treated with chemotherapy, 59 and 33% received at least two and three lines, res…

Malemedicine.medical_specialtyOrganoplatinum Compounds[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinAdenocarcinomaPopulation-basedTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIn patientRegistrieseducationAgedRetrospective StudiesMetastatic colon cancerChemotherapyeducation.field_of_studyHepatologyMetastatic colorectal cancerbusiness.industryPalliative CareComorbidity scoreAge FactorsGastroenterologyMiddle Aged3. Good healthCancer registry[SDV] Life Sciences [q-bio]Population based study030220 oncology & carcinogenesisColonic NeoplasmsCamptothecinFemale030211 gastroenterology & hepatologyFluorouracilFrancebusiness
researchProduct

Expression of α-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett’s esophagus

2008

Two different studies demonstrated alpha-methylacyl coenzyme A racemase (AMACR) to be a highly specific marker in Barrett's neoplastic lesions. Reactive atypia was positive in 3/30 cases in these studies. We present a retrospective study of early Barrett's adenocarcinoma treated with surgery (2000-2005, n=29; M:F=5:1, median age 67 years). We analyzed the role of AMACR expression in reactive and neoplastic lesions associated with the disease of 77 different specimens (60 biopsy and 17 surgical specimens) of these patients. In our cohort, 70% of cases demonstrated infiltration of the submucosa, 38% were poorly differentiated, and/or 31% demonstrated lymph vessel infiltration. We used a multi…

Malemedicine.medical_specialtyPathologyColumnar epithelial cellEsophageal NeoplasmsRacemases and EpimerasesAdenocarcinomaBiologyGastroenterologyPathology and Forensic MedicineBarrett EsophagusSubmucosaInternal medicineBiopsyBiomarkers TumormedicineAtypiaCarcinomaHumansAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testMiddle Agedmedicine.diseasedigestive system diseasesmedicine.anatomical_structureTissue Array AnalysisDysplasiaBarrett's esophagusAdenocarcinomaFemalePrecancerous ConditionsModern Pathology
researchProduct

Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients

2014

Few studies have investigated rectal cancer management at the population level. We compared how rectal cancers diagnosed in Italy (2003-2005) and France (2005) were managed, and evaluated the extent to which management adhered to European guidelines.Samples of 3938 Italian and 2287 French colorectal cancer patients were randomly extracted from 8 and 12 cancer registries respectively. Rectal cancer patients (860 Italian, 559 French) were analysed. Logistic regression models estimated odds ratios (ORs) of being treated with curative intent, receiving sphincter-saving surgery, and receiving preoperative radiotherapy.Similar proportions of Italian and French patients were treated with curative …

Malemedicine.medical_specialtyPreoperative radiotherapyPopulation levelColorectal cancer[SDV]Life Sciences [q-bio]Anal CanalAdenocarcinomaLogistic regressionInternal medicinemedicineHumansComputingMilieux_MISCELLANEOUSAgedAged 80 and overHepatologybusiness.industryRectal NeoplasmsGastroenterologyCancerOdds ratioMiddle Agedmedicine.diseaseNeoadjuvant Therapy3. Good healthSurgeryCancer registryPopulation based studyItalyPractice Guidelines as TopicLymph Node ExcisionFemaleRadiotherapy AdjuvantFranceGuideline AdherencebusinessOrgan Sparing Treatments
researchProduct

Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma

2018

Purpose: To compare imaging features of pancreatic metastases (PM) with those of pancreatic ductal adenocarcinomas (PDAC). Methods: CT and MR scans of 24 patients with 54 PM and 30 patients with PDAC were reviewed to evaluate the imaging features, which were compared by using a Chi square test. Results: We found a statistically significant difference between PM and PDAC based on location (P < 0.001), margins (P < 0.001), arterial enhancement (P = 0.004), rim enhancement (P < 0.001), pancreatic duct dilatation (P = 0.01), common bile duct dilatation (P = 0.003), vascular involvement (P = 0.02), parenchymal atrophy (P < 0.001), peripancreatic fluid (P = 0.03). Conclusion: Imaging features mig…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingPancreatic ductal adenocarcinomaLung Neoplasmsendocrine system diseasesMetastaseComputed tomographyAdenocarcinoma030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansAbdominal radiology; Adenocarcinoma; Computed tomography; Magnetic resonance; Metastases; Pancreas; Radiology Nuclear Medicine and ImagingPancreaPancreatic carcinomaCarcinoma Renal CellComputed tomographyAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industrySignificant differenceMagnetic resonance imagingNeoplasms Second PrimaryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAbdominal radiologydigestive system diseasesKidney NeoplasmsPancreatic Neoplasmsmedicine.anatomical_structureMagnetic resonance030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologybusinessPancreasTomography X-Ray ComputedCarcinoma Pancreatic Ductal
researchProduct

Robotic-assisted pancreaticoduodenectomy with vascular resection. Description of the surgical technique and analysis of early outcomes

2019

Abstract Background Despite the potential benefits, the adoption of the minimally invasive surgery for the treatment of borderline resectable pancreatic cancer is still in the initial phase. We investigated the safety and feasibility of the robotic pancreaticoduodenectomy with venous resection/reconstruction (RPD SMV/PV). Methods Since March 2013 to October 2019, a total of 73 RPD and 10 RPD SMV/PV were performed. The two groups were case-matched according to the preoperative characteristics. Results Mean operative times and estimated blood loss were less in the RPD group in comparison to that in the RPD with SMV-PV group (525 vs 642 min, p = 0.003 and 290 vs 620 ml, p = 0.002, respectively…

Malemedicine.medical_specialtyRobotic assistedmedicine.medical_treatmentOperative TimeAdenocarcinoma030230 surgeryPancreaticoduodenectomy03 medical and health sciences0302 clinical medicineRobotic Surgical ProceduresBorderline resectablePancreatic cancerVascular reconstructionHumansMedicineRobotic surgeryVascular resectionAgedbusiness.industryMortality rateSurgical outcomesRobotic surgeryMiddle Agedmedicine.diseasePancreaticoduodenectomySurgeryPancreatic NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisInitial phaseFemaleSurgerybusinessVascular Surgical Procedures
researchProduct

Impact of structured report on the quality of preoperative CT staging of pancreatic ductal adenocarcinoma: assessment of intra- and inter-reader vari…

2019

Purpose: To evaluate whether a structured radiology report improves the completeness of preoperative CT staging of pancreatic ductal adenocarcinoma (PDA) compared to conventional free-text reports. Methods: We retrospectively included 27 patients (mean age, 64 ± 11.1 years) referred for pancreatic preoperative CT scan for staging of PDA between 2015 and 2018 and in whom a diagnosis of pancreatic adenocarcinoma was ultimately confirmed. Four readers independently reported CT scans with both conventional free-text and structured reports. Differences in reported morphologic and vascular features with the two reports were assessed through McNemar Test. Intra-reader and inter-reader were calcula…

Malemedicine.medical_specialtyStructured ReportingLeft gastric arteryUrologyPancreatic Cancer StagingPancreatic Ductal AdenocarcinomaAdenocarcinomaSplenic artery030218 nuclear medicine & medical imagingGastroduodenal artery03 medical and health sciences0302 clinical medicineMcNemar's testComputed Tomographymedicine.arteryStructured reportingmedicineHumansRadiology Nuclear Medicine and imagingSuperior mesenteric veinAgedNeoplasm StagingRetrospective StudiesAged 80 and overRadiological and Ultrasound Technologybusiness.industryGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseasePancreatic NeoplasmsSplenic vein030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologyTomography X-Ray ComputedbusinessCarcinoma Pancreatic Ductal
researchProduct

Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia

2005

Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has proven to be safe and effective in patients with early neoplasia in Barrett's esophagus. However, long-term results in patients with high-grade intraepithelial neoplasia (HGIN) or with early cancer are still lacking.The aim of the study was to evaluate the efficacy of ALA-PDT and the survival of patients with early Barrett's neoplasia. ALA-PDT was carried out in 66 patients. Protoporphyrin IX induced by oral administration of ALA (60 mg/kg body weight orally applied 4-6 hours before PDT) was used as the photosensitizer. Acid suppression was maintained in all patients.Between September 1996 and September 2002, 667 patients with …

Malemedicine.medical_specialtyTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentPhotodynamic therapyAdenocarcinomaSeverity of Illness IndexGastroenterologyDisease-Free SurvivalBarrett EsophagusGermanyInternal medicineHumansMedicineRadiology Nuclear Medicine and imagingEsophagusSurvival rateAgedNeoplasm StagingRetrospective StudiesIntraepithelial neoplasiaPhotosensitizing Agentsbusiness.industryGastroenterologyCancerAminolevulinic AcidMiddle Agedmedicine.diseaseSurvival RateTreatment Outcomemedicine.anatomical_structurePhotochemotherapyEsophagectomyHigh Grade Intraepithelial NeoplasiaAdenocarcinomaFemalebusinessPrecancerous ConditionsFollow-Up StudiesGastrointestinal Endoscopy
researchProduct

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a m…

2006

ABSTRACT Background: Combinations of gemcitabine–oxaliplatin, gemcitabine–5-fluorouracil (5-FU) and 5-FU–oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine–oxaliplatin and infusional 5-FU in patients with locally advanced (n = 11) or metastatic (n = 32) pancreatic adenocarcinoma. Patients and methods: A total of 43 eligible patients were treated with intravenous infusions of gemcitabine (900 mg/m2 over 30 min), followed by oxaliplatin (65 mg/m2 over 2 h) and 5-FU (1500 mg/m2 over 24 h) on days 1 and 8 of a 21-day cycle. Results: Among all 43 patients, the tumor response rate was 19% …

Malemedicine.medical_specialtyTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchAdenocarcinomaDeoxycytidineGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLost to follow-upInfusions IntravenousAgedChemotherapyCardiotoxicitybusiness.industryCombination chemotherapyHematologyMiddle AgedGemcitabineChemotherapy regimenGemcitabineSurgeryOxaliplatinOxaliplatinPancreatic NeoplasmsSurvival RateTreatment OutcomeOncologyDisease ProgressionQuality of LifeFemaleFluorouracilbusinessmedicine.drugAnnals of Oncology
researchProduct

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

1980

Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression o…

Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessBritish journal of urology
researchProduct

Treatment of Severe Post-Prostatectomy Stress Urinary Incontinence Using Advance Sling

2010

Severe stress urinary incontinence (SUI) is usually treated by the implant of artificial sphincter positioned around bulbar urethra. AdVance sling is a functional, non-obstructive, anti-incontinence device that showed good results especially for mild and moderate SUI. We present our experience with AdVance sling in 7 patients with severe SUI unfit for artificial sphincter. Our results, after a follow-up of more than 6 months, showed a continence rate of 28% and an improvement rate of 43%, while 2 patients did not show any benefit. The success of AdVance sling depends on the integrity of urethral sphincter and can be applied also in selected cases for the treatment of severe post-prostatect…

Malemedicine.medical_specialtyUrinary Incontinence Stressmedicine.medical_treatmentUrologyUrinary incontinenceAdenocarcinomaDiabetes ComplicationsProsthesis ImplantationPostoperative ComplicationsHumansMedicinePost prostatectomyAgedRetrospective StudiesProstatectomybusiness.industryProstatectomyUrethral sphincterProstatic NeoplasmsRetrospective cohort studyProstheses and ImplantsGeneral MedicineMiddle AgedAdvance slingCombined Modality TherapyTreatment OutcomeChemotherapy AdjuvantImprovement rateHypertensionRadiotherapy AdjuvantImplantmedicine.symptombusinessUrologia Journal
researchProduct